Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Market Cap	$3.08B	P/E Ratio	N/A
52W High	$82.42	52W Low	$38.51
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-66.1%	52W Position	93.7%
Overall Score	55	Value Score	40
Quality Score	--	Technical Score	70

EPS Current Est	$-1.53	EPS Next Est	$1.05
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TARS	$79.66	+3.48%	433.05K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TARS	$79.66	+3.5%	433.05K
3
4
5
6

TARS

TARS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Tarsus Pharmaceuticals Inc. Data in Excel

Get Tarsus Pharmaceuticals Inc. Data in Excel